GIMBHI’s daily mental health update — 06/11/26

💰 Aetna leads commercial payers in psychotherapy reimbursement at $156 per session (Behavioral Health Business) — 06/09/26
TL;DR: Allia Health’s dashboard of Transparency in Coverage data shows Aetna’s median 60-minute psychotherapy rate is $156 vs. Cigna’s $120, with therapist enablement platforms like Alma negotiating higher rates than traditional providers like Cerebral, even as Aetna plans July rate cuts for Alma-contracted therapists.

🎙️ ASCP podcast challenges diagnosis-based frameworks in suicide research and prevention (Psychiatric Times) — 06/11/26
TL;DR: In the inaugural “Psychopharm Today” episode, AFSP’s Harkavy-Friedman and NIMH’s Ballard argue suicide has distinct biology beyond depression, and that diagnosis-focused studies excluding suicidal individuals limit development of targeted interventions.

🤖 Anthropic launches Claude Fable 5 and Mythos 5 with built-in safeguards (MobiHealthNews) — 06/10/26
TL;DR: Anthropic released Fable 5 and the restricted Mythos 5, which accelerated drug discovery ~10x and autonomously conducted genomics research, but routes sensitive biology and chemistry queries to a lower-capability model to mitigate biosecurity risks.

🏫 Nearly 6 million English children can now access mental health support in schools (Social Care Today) — 06/10/26
TL;DR: Mental health support teams now operate in nearly 11,800 English schools and colleges — up 800,000 children from last year — with 9 in 10 schools reporting wellbeing improvements and 7 in 10 reporting better attendance, as the government targets universal school access by 2029.